Wells Fargo analyst Derek Archila maintains $Septerna (SEPN.US)$ with a buy rating, and maintains the target price at $43.
According to TipRanks data, the analyst has a success rate of 46.3% and a total average return of 10.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Septerna (SEPN.US)$'s main analysts recently are as follows:
Septerna is noted for its unique position within the broader biopharma landscape, by deploying predictive high-throughput screening along with SAR optimization focussed on G protein-coupled receptor targets. The company's strategic execution of a highly attractive pipeline, targeting validated entities in substantial, established indications where an oral option presents a clear advantage to patients, is particularly noteworthy.
There is potential upside for the shares based on the Phase 1 results of SEP-786, considered to be promising due to existing data from similar parathyroid hormone programs. Septerna's SEP-631 is regarded as a significant but unrecognized asset. The company's Native Complex platform approach and the preclinical data of SEP-786 are expected to effectively transition into clinical stages.
The company is leveraging its Native Complex platform to develop a pipeline of oral small molecule G protein-coupled receptor drugs. There is seen as significant potential for stock appreciation rooted in validated targets within sizable markets.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富國集團分析師Derek Archila維持$Septerna (SEPN.US)$買入評級，維持目標價43美元。
根據TipRanks數據顯示，該分析師近一年總勝率為46.3%，總平均回報率為10.0%。
此外，綜合報道，$Septerna (SEPN.US)$近期主要分析師觀點如下：
塞普特納以在更廣泛的生物製藥領域中的獨特地位而聞名，通過部署預測性高通量篩選以及重點關注G蛋白偶聯受體靶點的SAR優化。該公司對高度引人注目的流水線的戰略執行，針對已驗證的實體在實質性、成熟的適應症中，口服選擇對患者具有明顯優勢，特別值得一提。
根據SEP-786的I期結果，股票存在上漲潛力，由於類似甲狀旁腺素藥物方案的現有數據被認爲是有希望的。塞普特納的SEP-631被認爲是一項重要但未被認識的資產。該公司的Native Complex平台方法以及SEP-786的臨床前數據預計能夠有效過渡到臨床階段。
該公司正利用其Native Complex平台開發一系列口服小分子G蛋白偶聯受體藥物流水線。在規模龐大市場中已驗證靶向的股票升值潛力被視爲顯著。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
